70results about "Keratin" patented technology

Present invention teaches the method of using a keratin hydrolysis peptide (“KHP”) solution to improve the efficacy of fertilizer usage and absorption by soybeans. By selectively choosing specific weights of feathers and water, and treating the mixture to a high-temperature high-pressure hydrolysis process, the resulting solution is confirmed to contain at least 253 peptides and then infused to the fertilized soil in which the soybean seeds are grown, as well as the plants after the seed start sprouting. Optionally, the KHP solution can be diluted by water, as disclosed in the specification, for applying to the soil around the soybean.

Relates to the technical field of medicines, provides keratin CF5, a preparation method, a pharmaceutical composition and application thereof, and particularly relates to keratin CF5, a nucleic acid molecule for coding the keratin CF5, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method of the keratin CF5. The invention relates to a keratin CF5-containing pharmaceutical composition and application of the keratin CF5, nucleic acid molecules, expression vectors, host cells or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating drugs, anticonvulsion, antiepilepsy, blood pressure lowering drugs, anti-inflammatory drugs and antiviral drugs, in particular to application of the keratin CF5, the nucleic acid molecules, the expression vectors, the host cells or the pharmaceutical composition in preparation of antipyretic and analgesic drugs.

Belongs to the technical field of medicine, and provides keratin CF7, a preparation method, a pharmaceutical composition and application thereof. Specifically, the invention provides keratin CF7, a nucleic acid molecule encoding the keratin CF7, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF7, a pharmaceutical composition containing the keratin CF7, and a preparation method of the keratin CF7. The invention also discloses application of the keratin CF7, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating, anti-convulsion, anti-epilepsy, antihypertensive, anti-inflammatory and antiviral drugs.

The invention provides keratin CF3 as well as a preparation method, a pharmaceutical composition and application thereof, and belongs to the technical field of medicines. Specifically, the invention provides keratin CF3, a nucleic acid molecule encoding the keratin CF3, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF3, a pharmaceutical composition containing the keratin CF3, and a preparation method of the keratin CF3. The invention also discloses application of the keratin CF3, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic drugs, antitussive and expectorant drugs, anticonvulsion drugs, antiepileptic drugs, antihypertensive drugs, anti-inflammatory drugs and antiviral drugs.

The invention provides keratin CF4 as well as a preparation method, a pharmaceutical composition and application thereof, and belongs to the technical field of medicines. Specifically, the invention provides keratin CF4, a nucleic acid molecule encoding the keratin CF4, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF4, a pharmaceutical composition containing the keratin CF4, and a preparation method of the keratin CF4. The invention also discloses application of the keratin CF4, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic drugs, antitussive and expectorant drugs, anticonvulsion drugs, antiepileptic drugs, antihypertensive drugs, anti-inflammatory drugs and antiviral drugs.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

Belongs to the technical field of medicines, and relates to keratin CF1, a preparation method, a pharmaceutical composition and application thereof, in particular to keratin CF1, a nucleic acid molecule for encoding keratin CFI, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method of the keratin CF1. The invention relates to a keratin CF1-containing pharmaceutical composition and application of the keratin CF1, nucleic acid molecules, expression vectors, host cells or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating drugs, anticonvulsion, antiepilepsy, blood pressure lowering drugs, anti-inflammatory drugs and antiviral drugs, in particular to application of the keratin CF1, the nucleic acid molecules, the expression vectors, the host cells or the pharmaceutical composition in preparation of antipyretic and analgesic drugs.

Belongs to the technical field of medicines, discloses keratin CF2, a preparation method, a pharmaceutical composition and application thereof, and particularly relates to keratin CF2, a nucleic acid molecule for encoding the keratin CF2, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method of the keratin CF2. The invention relates to a keratin CF2-containing pharmaceutical composition and application of the keratin CF2, nucleic acid molecules, expression vectors, host cells or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating drugs, anticonvulsion, antiepilepsy, blood pressure lowering drugs, anti-inflammatory drugs and antiviral drugs, in particular to application of the keratin CF2, the nucleic acid molecules, the expression vectors, the host cells or the pharmaceutical composition in preparation of antipyretic and analgesic drugs.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-8, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-8 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, breast cancer, lung cancer, analgesia, lactation, uterine fibroids, coagulation, etc.

Belongs to the technical field of medicine, and provides keratin CF8, a preparation method, a pharmaceutical composition and application thereof. Provided are a keratin CF8, a nucleic acid molecule encoding the keratin CF8, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF8, and a pharmaceutical composition containing the keratin CF8. The invention also discloses application of the keratin CF8, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating, anti-convulsion, anti-epilepsy, antihypertensive, anti-inflammatory and antiviral drugs.

The present invention provides a keratin BD-13, an encoding nucleic acid molecule, an expression vector, a host cell, a preparation method thereof, and a pharmaceutical composition containing the keratin. The keratin BD-13 can be used in the preparation of medicamnet for antipyretic, analgesic, antitussive, expectorant, anticonvulsant, antiepileptic, anti-hypertension, anti-inflammatory, and antiviral.

The invention belongs to the technical field of medicines, and relates to keratin CF12, a preparation method, a pharmaceutical composition and application thereof. Relates to a keratin CF12, a nucleic acid molecule for coding the keratin CF12, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF12, and a pharmaceutical composition containing the keratin CF12. The invention also discloses application of the keratin CF12, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic drugs, antitussive and expectorant drugs, anticonvulsion drugs, antiepileptic drugs, antihypertensive drugs, anti-inflammatory drugs and antiviral drugs.

The invention relates to the field of keratin extraction methods. More particularly, the invention relates to a method for extracting keratin, in particular human hair keratin, without chemical products. The method comprises three thermal hydrolysis steps. The keratin obtained is of high quality, the amino acid composition of same being close to that of native keratin, and can be used in applications with a high added value such as cosmetics or medical devices. The biomimicry between the keratin extracted from hair using this extraction method and natural keratin is more than 90%.

Provided herein is a method of improving the solubility of a recombinantly produced polypeptide of interest, by expressing the polypeptide of interest together with a solubility-enhancing amino acid sequence.

The application provides a KRT31 gene knockout cell line and its application in promoting replication of viruses of the Picornaviridae family and / or production of vaccines of viruses of the Picornaviridae family, and belongs to the technical field of genetic engineering. The application provides an application of a KRT31 gene or a coded protein thereof as a target in preparation of a product for regulating replication of viruses of the Picornaviridae family and / or vaccine production. Up-regulation of the expression level of the KRT31 gene can inhibit replication of viruses of the Picornaviridae family, and down-regulation of the expression level of the KRT31 gene can promote replication of viruses of the Picornaviridae family. The application adopts sgRNA to knockout the KRT31 gene to prepare a cell line with lost function of a gene coded protein, so as to promote replication of viruses of the Picornaviridae family, improve virus titer and antigen yield, and help to efficiently prepare vaccines of viruses of the Picornaviridae family.

Provided herein are fusion proteins / peptides and biopolymers comprising keratin and keratin associated peptide sequences. The fusion proteins and biopolymers may further comprise elastin-like, silk-like, collagen or collagen-like, resilin-like, abductin-like peptide, and / or linker-like sequences. The fusion proteins and biopolymers may exhibit the functional properties derived from each of the various peptide sequences incorporated therein, like elasticity, hydration, recovery, texture, or antimicrobial and UV protections. Additionally, provided herein are methods for obtaining and characterization of fusion proteins and biopolymers comprising keratin and keratin associated peptide sequences. The fusion proteins and biopolymers comprising keratin and keratin associated peptide sequences may be included in compositions for improving the properties of hair, skin, and nails.

The present invention relates to the technical field of medicines, provides a keratin CF5, a preparation method, a pharmaceutical composition containing same, and a use of the keratin CF5, and specifically relates to a keratin CF5, a nucleic acid molecule encoding the keratin CF5, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or the nucleic acid molecule integrated into a genome, a preparation method for the keratin CF5, a pharmaceutical composition containing the keratin CF5, and a use of the keratin CF5, the nucleic acid molecule, the expression vector, the host cell, or the pharmaceutical composition in preparation of drugs having antipyretic and analgesic, antitussive and expectorant, anticonvulsant, antiepileptic, antihypertensive, anti-inflammatory and antiviral effects.

The invention relates to the field of keratin extraction processes. More particularly, the invention relates to a process for extracting keratin of human origin from hair, without chemicals. The keratin obtained is of high quality, its amino acid composition being close to that of native keratin, and can be used in high value-added applications such as cosmetics or medical devices. The biomimicry between the keratin extracted by this extraction process and the natural keratin of the hair is more than 90%.

The present application relates to keratin protein extracts, compositions, methods and uses thereof. In some embodiments, the keratin protein extract is a beta-keratin extract. In some embodiments, the compositions are beta-keratin compositions. In some embodiments, the methods are methods of cleaning a keratin source material, methods of extracting beta-keratin, methods of preparing keratin compositions, and methods of using keratin protein extracts and compositions.

Provided herein are compositions comprising a polypeptide and an excipient, wherein the polypeptide comprises a keratin or keratin associated peptide block and one or more polypeptide blocks. In some embodiments, the excipient comprises an emollient, an emulsifier, a conditioning agent, vitamin E or derivative thereof, a ceramide, a lipid nanoparticle dispersion, a hair conditioner, a skin conditioner, a cleansing agent, a detoxifying agent, or a combination thereof. Provided herein are methods for using the compositions for treating hair.

The invention belongs to the technical field of medicines, and relates to keratin CF14, a nucleic acid molecule encoding the keratin CF14, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF14, a pharmaceutical composition containing the keratin CF14, and a preparation method of the keratin CF14. The invention also discloses application of the keratin CF14, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic drugs, antitussive and expectorant drugs, anticonvulsion drugs, antiepileptic drugs, antihypertensive drugs, anti-inflammatory drugs and antiviral drugs.

The present invention relates to the technical field of medicines, provides a keratin CF7, a preparation method therefor, a pharmaceutical composition containing same, and a use of keratin CF7, and specifically provides keratin CF7, a nucleic acid molecule encoding keratin CF7, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or the nucleic acid molecule integrated into a genome, a preparation method for keratin CF7, a pharmaceutical composition containing keratin CF7, and a use of keratin CF7, the nucleic acid molecule, the expression vector, the host cell, or the pharmaceutical composition in preparation of drugs having antipyretic and analgesic, antitussive and expectorant, anticonvulsant, antiepileptic, antihypertensive, anti-inflammatory and antiviral effects.

The present invention provides a non-human animal having a novel fiber and a method for preparing the non-human animal. Specifically, the present invention provides a non-human animal with reduced expression or functions of at least one gene constituting the Krt or KAP family, and a method for preparing the non-human animal.

The invention relates to a method for extracting collagen and keratin in sheep fur, belongs to the technical field of biochemistry, and aims to solve the problems of protein structure damage and low product purity caused by low degreasing efficiency and extensive cracking in the traditional process. According to the method, a mixed solution containing sodium carbonate and magnetic nanoparticle immobilized lipase is adopted for composite degreasing treatment, and intermittent ultrasonic assistance is applied to improve the degreasing effect; in the reduction cracking treatment, the cracking conditions are optimized through staged gradient heating and adding EDTA-Na2 in batches; in the keratin gradient precipitation, ammonium sulfate with different saturations is used for fractional precipitation, and vertical vibration is applied to improve separation; the activity stability of pepsin is maintained through a closed-loop pH control system by dynamic enzymolysis; and the collagen retention rate is improved by adopting a pore size gradient composite membrane in series ultrafiltration purification. According to the method, the protein extraction efficiency and purity are remarkably improved, and the method is suitable for preparing high-quality collagen and keratin raw materials in the fields of biological medicine, cosmetics and material science.

Disclosed herein are methods, uses and compositions for the treatment or prophylaxis of cancer in a mammalian subject comprising administering to the subject an amount of an agent which targets an extracellular portion of KRT14 or its functional homolog or variant thereof resident on cancer cells or an agent which induces production of an antagonist of the extracellular portion of KRT14 or its functional homolog or variant on cancer cells. The present disclosure also extends to methods of monitoring and / or diagnosing cancer in a subject.

Fusion proteins / peptides and biopolymers containing keratin and keratin-related peptide sequences are provided herein. The fusion proteins and biopolymers may further comprise elastin-like, silk-like, collagen or collagen-like, resilin-like, abductin-like peptides, and / or linker-like sequences. The fusion proteins and biopolymers may exhibit functional properties derived from the various peptide sequences incorporated therein, such as elasticity, moisture retention, recovery, texture, or antibacterial and UV protection. Additionally, methods for obtaining and characterizing fusion proteins and biopolymers containing keratin and keratin-related peptide sequences are provided herein. Fusion proteins and biopolymers containing keratin and keratin-related peptide sequences can be included in compositions for improving the properties of hair, skin, and nails.

Peptides having an amino acid sequence selected from the group consisting of SEQ ID NO:2 to SEQ ID NO:20, as well as pharmaceutical compositions comprising said peptides. Pharmaceutical compositions for the treatment or prevention of infections caused by viruses which infect epithelial cells of the mammalian respiratory system, comprising a peptide having an amino acid sequence identified as SEQ ID NO:1. The invention includes the use of peptides having an amino acid sequence identified as SEQ ID NO:1 to SEQ ID NO:20 for the manufacture of a medicament for the treatment or prevention of infections caused by viruses which infect epithelial cells of the mammalian respiratory system. Also disclosed is the combination of at least one peptide of an amino acid sequence identified as SEQ ID NO:1 to SEQ ID NO:20 with an antiviral medicament.

The present disclosure relates to a process to assemble proteins derived from platelet lysates in bioactive microparticles, with increased surface organization. The present invention further relates to protein-based biomaterials applicable to biomedical and biotechnology fields, more precisely in tissue engineering strategies, disease modeling, and other biomedical applications. Namely, a method for obtaining a protein microparticle from a platelet lysate comprising the following steps: lyophilizing the platelet lysate; dissolving the lyophilized platelet lysate in phosphate buffer saline to obtain a platelet lysate solution; adding a reducing agent to the platelet lysate solution to obtain a reduced platelet lysate solution; adding an oxidizing agent to the reduced platelet lysate solution to form the microparticles by precipitation.

Provided herein are fusion proteins / peptides and biopolymers comprising a keratin and a peptide sequence associated with the keratin. These fusion proteins and biopolymers may further comprise an elastin-like, silk-like, collagen or collagen-like, arthropod elastin-like, abexin-like peptide and / or linker-like sequences. These fusion proteins and biopolymers may exhibit functional properties derived from each peptide sequence contained therein, such as elasticity, hydration, restorability, texture or antimicrobial and UV protection, etc. In addition, provided herein are methods of obtaining and characterizing fusion proteins and biopolymers comprising keratin and peptide sequences associated with keratin. Fusion proteins and biopolymers comprising keratin and peptide sequences associated with keratin may be included in compositions for improving the properties of hair, skin and nails.